Aripiprazole/sertraline

Aripiprazole/sertraline
Combination of
Sertraline	Selective serotonin reuptake inhibitor
Aripiprazole	Atypical antipsychotic
Clinical data
Synonyms	ASC-01
Routes of; administration	Oral
Legal status
Legal status	US: Investigational New Drug;

Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD).^[1] The drug combines serotonin reuptake inhibition and modulation of serotonin and dopamine receptors.^[1] As of 2016, it is in phase III clinical trials for MDD.^[1]

References[edit]

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.